[28-April-2020] LUND, Sweden , April 28, 2020 /PRNewswire/ -- Immunovia has today published first quarter interim report for January - March 2020 . It is available on Immunovia’s website . “During Q1 2020, Immunovia worked hard and continued to make great strides towards IMMray™ PanCan-d’s launch and the sales start of the first test for early diagnosis of pancreatic cancer, in spite of
| LUND, Sweden, April 28, 2020 /PRNewswire/ -- Immunovia has today published first quarter interim report for January - March 2020. It is available on Immunovia’s website. “During Q1 2020, Immunovia worked hard and continued to make great strides towards IMMray™ PanCan-d’s launch and the sales start of the first test for early diagnosis of pancreatic cancer, in spite of the COVID-19 global pandemic. Work on the verification study proceeded as planned and we received all the blood samples from our KOL network. In January, our commercial team prepared detailed plans for the launch and in March and April these plans were adapted significantly to accommodate the COVID-19 situation. This included making in-person activities, such as conferences and the patient organization meetings that were canceled, into digital activities, etc. In January, Immunovia welcomed a new Senior VP Sales NA (North America), Michael Pettigrew, to the team. Michael brings with him a very successful track record in product launches and sales growth in life science, along with unique leadership qualities. He is an important addition to Immunovia. Following the end of Q1 2020, we provided an update on the measures the company has taken and continues to take in order to support patients, employees and public health initiatives in response to the COVID-19 pandemic. We also announced other crucial preparations that Immunovia has made in response to COVID-19, such as securing inventories of critical consumables, the successful collection of samples for the verification study including the reallocation of extra blood samples to the efforts of securing all samples for the verification study. All this done to facilitate the uninterrupted continuation towards commercialization start. We reiterate that Immunovia’s R&D laboratories and clinical laboratory in Lund, along with the production facilities are fully operational. They all have plans in place to help sustain operations in these unusual times.” - Excerpt from the CEO Mats Grahn’s comment on the report First Quarter Interim Report for January - March 2020 Call Details: Immunovia invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET. Mats Grahn, CEO will present Immunovia and comment on the first quarter interim report for the period January - March 2020 followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator: Conference Numbers: Sweden: +46 (0)8-50520424 United Sates: +1-212-999-6659 France: +33-(0)1-7099-4740 Denmark: +45-3271-4573 Germany: +49(0)-69-7104-45598 Spain: +34-91-788-9854 Netherlands: +31(0)-20-794-8426 Norway: +47-2-156-3318 Austria: +43(0)12530807 Switzerland: +41(0)43-456-9986 UK (standard international access): +44(0)20-3003-2666 Conference Code: (to provide to the operator) Immunovia Immunovia Webcast: https://channel.royalcast.com/ webcast / immunovia / 20200428_1 / There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended. This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on April 28, 2020. About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
For more information, please contact: This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Immunovia AB | ||
Company Codes: Berlin:0G8X, Bloomberg:IMMNOV@SS, ISIN:SE0006091997, OTC-PINK:IMMVF, RICS:IMMNOV.ST, Stockholm:IMMNOV, LSE:0G8X |
View original content:
